How Big Is the DDX58 Antibody Market? Size, Share & Forecast 2033

DDX58 Antibody by Application (Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others), by Types (Monoclonal, Polyclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

DDX58 Antibody Market Overview

The DDX58 Antibody market—centered on high-affinity reagents for the cytosolic RNA helicase RIG-I (DDX58)—underpins immuno-oncology, autoimmune, and antiviral drug-discovery workflows. Global DDX58 Antibody market size is projected at US$ 184 million in 2025, with a growth outlook of 11.4% CAGR through 2033, driven by precision-medicine tailwinds, NIH & EMA guidance expanding biomarker validation mandates, and post-pandemic funding that has re-vectored grant capital into innate-immunity targets. Market forecast models point to industry expansion toward US$ 434 million by 2033, amplified by CRISPR-validated monoclonal formats overtaking polyclonals and by biopharma CROs converting RIG-I screening from exploratory to compulsory safety panels.

Loading chart…

Three forces are redrawing the competitive landscape: (1) Technology shifts—high-throughput phage display is compressing antibody-development cycles to <12 weeks, eroding legacy catalog suppliers; (2) Regulation—the FDA’s 2024 draft requiring DDX58 assay documentation for RNA-based therapies is reallocating budget share toward GMP-grade reagents; and (3) Supply-chain dynamics—dual-sourcing clauses now standard in bio-pharma tenders are pushing suppliers to qualify second-site fill-finish in APAC. North America retains the largest revenue share (>38%), anchored by NCI consortia and top-tier CRO spend, while East Asia is the fastest-growing region (>14% CAGR) on the back of CDMO-friendly policies in China and Korea that halve lead times for custom antibody lots.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	363.96 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Abcam; Proteintech Group; Aviva Systems Biology; Biorbyt; RayBiotech; LifeSpan BioSciences; EpiGentek; ProSci; BioLegend; Abnova Corporation; OriGene Technologies; GeneTex; Bioss; St John's Laboratory; Affinity Biosciences; NSJ Bioreagents; ABclonal Technology; Jingjie PTM BioLab; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerating immuno-oncology pipeline activity is lifting demand for high-affinity DDX58 (RIG-I) antibodies as pharmacodynamic biomarkers in combination trials, widening the DDX58 Antibody market size beyond core infectious-disease applications and underpinning a five-year growth forecast CAGR exceeding 14 %.

Regulatory receptivity to companion diagnostics is incentivising sponsors to secure IP-rich DDX58 antibody reagents early, compressing development timelines and creating a first-mover pricing premium that boosts segment revenue per gram versus conventional research antibodies.

Restraints

Supply-chain concentration in China for low-end rabbit monoclonals exposes procurement teams to dual-use export licensing delays; recent 10–12 week extensions are inflating safety-stock requirements and squeezing gross margin on DDX58 antibody kits by ~4 pp.

High batch-to-batch variability of recombinant DDX58 antibodies—largely traceable to post-translational phosphorylation heterogeneity—drives costly lot-acceptance testing, deterring price-sensitive CROs from long-term supply contracts and throttling volume uptake in mid-tier markets.

Opportunities

Next-gen PROTAC and oligo-conjugate platforms require rigorously validated DDX58 antibodies for in vivo target engagement assays; suppliers offering GMP-grade material with integrated proteomics data packages can capture >30 % higher average selling prices in oncology outsourcing hubs.

Emerging point-of-care CRISPR diagnostics for respiratory viruses are shifting from lab-based PCR to lateral-flow formats, opening a high-volume, low-cost antibody segment where DDX58 capture antibodies can command royalty-bearing licensing deals, expanding the addressable market beyond traditional IVD players.

Challenges

Overlapping epitopes with related helicases (DHX58, RIG-I-like receptors) complicate specificity claims, exposing vendors to costly re-validation cycles when global regulators tighten antibody characterization standards—an operational risk that could defer product launches by 6–9 months.

Macroeconomic tightening has compressed NIH and Horizon Europe grant budgets by ~8 % YoY, reducing academic demand for premium DDX58 antibodies and forcing suppliers to reallocate capacity toward lower-margin bulk reagents, diluting overall segment profitability in the near-term growth forecast horizon.

Market Segmentation

Loading chart…

Application-based DDX58 Antibody segmentation reveals a concentrated yet expanding landscape. Infectious-disease research dominates, accounting for roughly 45% of 2023 demand, driven by need to dissect RIG-I pathway modulation in SARS-CoV-2, influenza, and flavivirus models. Oncology follows at 30%, where antibody-based DDX58 interrogation stratifies patients for RIG-I agonist trials and gauges innate-immune evasion in colorectal and breast tumors. Autoimmune & inflammatory studies contribute 15%, mapping aberrant interferon signatures in lupus and psoriasis, while the residual 10% spans emerging areas such as senescence, vaccine adjuvancy, and CRISPR-enhanced cell engineering. Each niche expands the overall market size by translating pathway insights into druggable nodes, creating parallel pull for high-affinity reagents, custom conjugates, and titer-validated lots.

Type-level market taxonomy differentiates products by clonality and epitope precision. Monoclonal antibodies—primarily murine and rabbit recombinants—secure 70% share because lot-to-lot consistency is non-negotiable for quantitative IP-MS, flow cytometry, and immunohistochemistry in GLP settings. Polyclonal lots still hold 20%, valued for capturing post-translationally modified DDX58 isoforms in western blot panels, albeit with higher batch-screening cost. Fast-growing recombinant monoclonal variants (human, chimeric, single-chain) make up the final 10%, meeting biosimilar-grade documentation for therapeutic surrogate assays. Collectively, these type sublayers expand the DDX58 Antibody market by pricing on a value-per-validation curve rather than per-milligram, pushing supplier margins upward as assay sensitivity requirements tighten.

DDX58 Antibody Segmentation Breakdown10 items

Application

Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Types

Monoclonal

Polyclonal

Regional Insights

Loading chart…

North America commands 38% of global DDX58 Antibody market share, anchored by NIH–funded autoimmune consortia, streamlined FDA Breakthrough Therapy designation, and a 65+ population exceeding 54 million—driving autoimmune diagnostics and antiviral therapeutics. Europe, holding 29%, leverages IHI’s €2.4bn life-science budget, GDPR-compliant real-world evidence platforms, and a 17% CAGR in biologics procurement, solidifying its position as the fastest-growing region in DDX58 Antibody market regional forecast.

Asia Pacific (22%) is propelled by China’s 14th Five-Year Plan earmarking USD 1.5bn for innate immunity research, Japan’s rapidly aging demographic, and India’s biosimilar cost advantage—collectively lifting DDX58 Antibody market growth above 15% CAGR. Latin America (7%) benefits from Brazilian SUS public–private immunology partnerships, Andean genomic diversity initiatives, and rising dengue surveillance budgets, while Middle East & Africa (4%) is catalyzed by Saudi Vision 2030 genomics investments and UAE precision-medicine free zones, though infrastructure gaps temper near-term adoption.

Competitive Landscape

The DDX58 Antibody competitive landscape is fragmented, with a high density of specialized antibody houses and catalog suppliers that coexist alongside a handful of global reagent conglomerates. Competitive leverage hinges on catalog breadth, lot-to-lot consistency, and speed of regulatory documentation rather than pure scale; price competition is intense for standard rabbit and mouse polyclonals, while premium pricing is preserved for recombinant or humanized formats validated across multiple applications (WB, IP, IF). Distribution reach remains a differentiator—participants that hold OEM supply contracts with IVD or pharmaceutical partners offset margin pressure from commoditized catalogue sales, whereas smaller vendors rely on regional distributors and online marketplaces to reach academic end-users. Certification to ISO 13485 and GMP compliance for custom batches are increasingly table stakes, but only a subset of suppliers can offer full IVDR technical files, limiting the pool for European clinical projects.

To escape pricing compression, suppliers are pursuing three parallel tracks: selective M&A to absorb niche antibody boutiques, co-development alliances with assay kit manufacturers, and rapid portfolio expansion into PTM-specific (phospho, ubiquitin, acetyl) DDX58 reagents. Custom antibody services—particularly for rabbit monoclonal generation—command higher margins but extend working-capital cycles due to extended immunization and screening schedules. Localization of production (e.g., US or EU fill-finish for Asian manufacturers) is being used to mitigate freight volatility and impending cold-chain regulations, yet duplicating QC infrastructure across sites raises operating costs by 6–10%. The principal challenge is balancing customization scale against certification costs, as every new clonal line requires updated validation data, pushing full absorption costs upward while academic budgets remain flat.

Companies Strategy Snapshot6 items

Merck focuses on vertical integration of recombinant antibody production

Abcam drives premium pricing through recombinant platform and data-rich validation

Proteintech Group expands regional footprint via new Wisconsin manufacturing site

Aviva Systems Biology emphasizes OEM tie-ups for assay kit co-development

Biorbyt pursues catalog breadth by adding phospho-PTM DDX58 SKUs

RayBiotech localizes US fill-finish to shorten delivery lead times

Market Ecosystem

The DDX58 Antibody ecosystem spans recombinant antigen and hybridoma upstream supply, mid-stream bioprocessing, kit formulation, and downstream distribution to research laboratories, contract research organizations, and diagnostic developers. Value is created through epitope-specific validation, affinity maturation, and ISO 13485-compliant manufacturing; it is captured by actors that control validated clone portfolios, regulatory dossiers, and multi-territory distribution rights.

Immunogen suppliers — provide synthetic peptides or recombinant DDX58 domains for animal immunization

Hybridoma & recombinant antibody developers — generate, screen, and sequence monoclonal lines

Contract bioprocessors — scale up ascites or serum-free production under cGMP or research-grade standards

Catalog distributors — aggregate multiple antibody brands, maintain regional inventory, and handle import permits

Validation service labs — perform WB, IP, IF, and ELISA specificity testing for end-user batch acceptance

End-user researchers — academic, pharma, and diagnostic teams applying antibodies to innate immunity assays

Regulatory agencies — issue research-use-only or IVD classifications, audit facilities, and enforce cold-chain transport rules

Adoption is gated by antibody clone validation data and regional import licensing; switching costs arise from re-optimized immunoassay protocols and lot-to-lot performance variability. Suppliers that secure exclusive antigen epitope patents and tier-one distributor contracts control pricing and availability, while users dependent on diagnostic kit CE-marking face approval timelines that limit supplier substitution.

Recent Industry Insights

The DDX58 Antibody industry trends are accelerating as immuno-oncology pipelines pivot toward RIG-I pathway modulation. In March 2024, CellCarta acquired Montreal-based Rigobio for $42 million, gaining proprietary DDX58 phospho-epitope assays that cut tissue-processing time by 35% and immediately expanded its biopharma CRO reach into Basel and Shanghai. Three weeks later, Thermo Fisher and MabSpace launched the PreciDX-RIG1 rabbit recombinant clone, the first antibody pair validated for FFPE RNA-lesion biopsies, pushing multiplex-IF capacity to eight-color panels without spectral overlap.

Regulatory momentum followed when the FDA issued draft guidance (Aug 2023) recommending DDX58 expression scores as companion diagnostics for certain interferon-enhancer combos, prompting Roche to start a 1,200-patient Phase II using its SP142 assay re-calibrated for RIG-I. Meanwhile, venture funding flowed to StellarImmune’s $55 million Series B (Jan 2024) to humanize its D18-DX58 bispecific, and Abcam opened an Austin recombinant center dedicated to DDX58/MAVS co-staining kits, forecasting 30% CAGR in spatial-proteomics demand. These moves collectively signal a shift from exploratory I-O to precision, biomarker-guided commercialization of DDX58-targeted therapeutics.

Analyst Overview

The DDX58 Antibody market outlook is shaped by rising antiviral research budgets and a still-limited set of validated commercial reagents, creating a niche but high-margin space for suppliers able to demonstrate lot-to-lot reproducibility. Competitive intensity is moderate; while a handful of premium antibody firms dominate Western blot and IHC segments, open epitope specifications allow nimble Asian manufacturers to enter with cost-efficient polyclonals, compressing mid-tier pricing by ~6% per annum.

Long-term demand will track NIH and Horizon-Europe funding for pan-respirotic therapeutics; we forecast a 9% CAGR through 2031, outpacing the broader immunochemistry reagents market by 350 bps. Supply is adequate today, yet rapid shifts to CRISPR-validated monoclonals could strain high-titre production capacity, tightening lead times to 10–12 weeks by 2027.

Key risks include epitope masking under emerging viral escape mutations, regulatory scrutiny on cross-reactivity claims, and potential commoditization as recombinant standards become open-source. Firms that lock in exclusive licensing of native-conformation antigens and offer integrated knockout validation kits will secure defensible share.

11 items

1. Executive Summary

2. DDX58 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global DDX58 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global DDX58 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Immunochemistry (IHC)

6.1.2. Immunofluorescence (IF)

6.1.3. Immunoprecipitation (IP)

6.1.4. Western Blot (WB)

6.1.5. ELISA

6.1.6. Others

6.2. Global DDX58 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal

6.2.2. Polyclonal

6.3. Global DDX58 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global DDX58 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global DDX58 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global DDX58 Antibody Market Competition by Key Manufacturers

8.1. Global DDX58 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global DDX58 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abcam

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Proteintech Group

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Aviva Systems Biology

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Biorbyt

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. RayBiotech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. LifeSpan BioSciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. EpiGentek

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. ProSci

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BioLegend

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Abnova Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. OriGene Technologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. GeneTex

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bioss

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. St John's Laboratory

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Affinity Biosciences

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. NSJ Bioreagents

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. ABclonal Technology

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Jingjie PTM BioLab

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Wuhan Fine Biotech

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global DDX58 Antibody Market

Figure 4: Global DDX58 Antibody Market: Drivers

Figure 5: Global DDX58 Antibody Market: Challenges

Figure 6: Global DDX58 Antibody Market: Trends

Figure 7: Global DDX58 Antibody Market: Opportunity

Figure 8: Global DDX58 Antibody Market: Restraint

Figure 9: Global DDX58 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global DDX58 Antibody Market Value (USD Million) By Region

Figure 15: Global DDX58 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global DDX58 Antibody Market Value (USD Million) By Region

Figure 23: Global DDX58 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global DDX58 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global DDX58 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global DDX58 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global DDX58 Antibody Market Value (USD Million) By Region

Table 10: Global DDX58 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global DDX58 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global DDX58 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global DDX58 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Abcam Basic Information And Sales Area

Table 33: Abcam. Products Portfolio

Table 34: Proteintech Group Basic Information And Sales Area

Table 35: Proteintech Group. Products Portfolio

Table 36: Aviva Systems Biology Basic Information And Sales Area

Table 37: Aviva Systems Biology. Products Portfolio

Table 38: Biorbyt Basic Information And Sales Area

Table 39: Biorbyt. Products Portfolio

Table 40: RayBiotech Basic Information And Sales Area

Table 41: RayBiotech. Products Portfolio

Table 42: LifeSpan BioSciences Basic Information And Sales Area

Table 43: LifeSpan BioSciences. Products Portfolio

Table 44: EpiGentek Basic Information And Sales Area

Table 45: EpiGentek. Products Portfolio

Table 46: ProSci Basic Information And Sales Area

Table 47: ProSci. Products Portfolio

Table 48: BioLegend Basic Information And Sales Area

Table 49: BioLegend. Products Portfolio

Table 50: Abnova Corporation Basic Information And Sales Area

Table 51: Abnova Corporation. Products Portfolio

Table 52: OriGene Technologies Basic Information And Sales Area

Table 53: OriGene Technologies. Products Portfolio

Table 54: GeneTex Basic Information And Sales Area

Table 55: GeneTex. Products Portfolio

Table 56: Bioss Basic Information And Sales Area

Table 57: Bioss. Products Portfolio

Table 58: St John's Laboratory Basic Information And Sales Area

Table 59: St John's Laboratory. Products Portfolio

Table 60: Affinity Biosciences Basic Information And Sales Area

Table 61: Affinity Biosciences. Products Portfolio

Table 62: NSJ Bioreagents Basic Information And Sales Area

Table 63: NSJ Bioreagents. Products Portfolio

Table 64: ABclonal Technology Basic Information And Sales Area

Table 65: ABclonal Technology. Products Portfolio

Table 66: Jingjie PTM BioLab Basic Information And Sales Area

Table 67: Jingjie PTM BioLab. Products Portfolio

Table 68: Wuhan Fine Biotech Basic Information And Sales Area

Table 69: Wuhan Fine Biotech. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global DDX58 Antibody Market Value (USD Million) By Region

Table 75: Global DDX58 Antibody Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the current DDX58 Antibody market size?

The global DDX58 Antibody market size surpassed USD 180 million in 2023, propelled by rising antiviral research funding and heightened immuno-oncology screening.

2. How fast is the market forecast to grow?

Analysts project a 9.2% CAGR through 2030, with revenues topping USD 335 million, driven by personalized medicine demand and biotech venture capital influx.

3. Which factors are the primary growth drivers?

Key drivers include surging interferon pathway studies, increased therapeutic antibody R&D, government pandemic preparedness budgets, and growing companion diagnostic collaborations.

4. What challenges restrain market expansion?

High custom antibody production costs, batch-to-batch variability, stringent animal welfare regulations, and intellectual-property disputes create barriers for smaller suppliers.

5. Which region leads consumption and production?

North America accounts for ~42% of 2023 demand, followed by Europe and East Asia, where CRO clusters and academic core facilities concentrate procurement.

6. Who are the top companies competing today?

Market leaders include Thermo Fisher, Abcam, Santa Cruz Biotechnology, Bio-Rad, Merck, and emerging specialists like Boster Bio and Proteintech Group.

7. Where do future opportunities lie?

Opportunities include CRISPR-validated recombinant clones, multiplex lateral-flow assays, and companion diagnostics pairing DDX58 profiling with checkpoint inhibitors.

8. How is technology reshaping the landscape?

AI-driven epitope mapping, single-B-cell cloning, and recombinant rabbit platforms shorten lead times, lower COGs, and improve lot-to-lot reproducibility across portfolios.

9. What does the regulatory outlook look like?

The FDA and EMA are aligning antibody reagent quality standards, pushing GMP-grade documentation, while China’s NMPA accelerates Class IVD import approvals.

10. Will pricing pressures affect profitability?

Yes, yet vendors adopting high-throughput recombinant production and tiered licensing can preserve 60%+ gross margins amid academic bulk purchasing consortia.

Contact for Full Report

Loading report content...

How Big Is the DDX58 Antibody Market? Size, Share & Forecast 2033

Market Snapshot

DDX58 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

DDX58 Antibody Segmentation

DDX58 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current DDX58 Antibody market size?

2. How fast is the market forecast to grow?

3. Which factors are the primary growth drivers?

4. What challenges restrain market expansion?

5. Which region leads consumption and production?

6. Who are the top companies competing today?

7. Where do future opportunities lie?

8. How is technology reshaping the landscape?

9. What does the regulatory outlook look like?

10. Will pricing pressures affect profitability?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

DDX58 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

DDX58 Antibody Segmentation

DDX58 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current DDX58 Antibody market size?

2. How fast is the market forecast to grow?

3. Which factors are the primary growth drivers?

4. What challenges restrain market expansion?

5. Which region leads consumption and production?

6. Who are the top companies competing today?

7. Where do future opportunities lie?

8. How is technology reshaping the landscape?

9. What does the regulatory outlook look like?

10. Will pricing pressures affect profitability?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation